Analyzing transformation of myelodysplastic syndrome to secondary acute myeloid leukemia using a large patient database

• Published in: American journal of hematology 2012-09, Vol.87 (9), p.853-860
• Main Authors: Shukron, Ofir, Vainstein, Vladimir, Kündgen, Andrea, Germing, Ulrich, Agur, Zvia
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Biological and medical sciences; Databases, Factual; Female; Germany; Hematologic and hematopoietic diseases; Hematology; Hospitals, University; Humans; International Classification of Diseases; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute - diagnosis; Leukemia, Myeloid, Acute - mortality; Leukemia, Myeloid, Acute - pathology; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Male; Medical sciences; Middle Aged; Myelodysplastic Syndromes - diagnosis; Myelodysplastic Syndromes - mortality; Myelodysplastic Syndromes - pathology; Poisson Distribution; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk; Time Factors; Young Adult
• ISSN: 0361-8609; 1096-8652
• DOI: 10.1002/ajh.23257

One‐third of patients with myelodysplastic syndrome (MDS) progress to secondary acute myeloid leukemia (sAML), with its concomitant poor prognosis. Recently, multiple mutations have been identified in association with MDS‐to‐sAMLtransition, but it is still unclear whether all these mutations are necessary for transformation. If multiple independent mutations are required for the transformation, sAML risk should increase with time from MDS diagnosis. In contrast, if a single critical biological event determines sAML transformation; its risk should be constant in time elapsing from MDS diagnosis. To elucidate this question, we studied a database of 1079 patients with MDS. We classified patients according to the International Prognostic Scoring System (IPSS), using either the French‐American‐British (FAB) or the World Health Organization (WHO) criteria, and statistically analyzed the resulting transformation risk curves of each group. The risk of transformation after MDS diagnosis remained constant in time within three out of four risk groups, and in all four risk groups, when patients were classified according to FAB or to the WHO‐determined criteria, respectively. Further subdivision by blast percentage or cytogenetics had no influence on this result. Our analysis suggests that a single random biological event leads to transformation to sAML, thus calling for the exclusion of time since MDS diagnosis from the clinical decision‐making process. Am. J. Hematol. © 2012 Wiley Periodicals, Inc.